Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thiotepa + methotrexate
- Development stage
- Phase 2
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of thiotepa and high-dose methotrexate (HD-MTX). Thiotepa inhibits tumor growth by disrupting DNA bonds, while methotrexate is an antimetabolite that inhibits dihydrofolate reductase. This combination is primarily used in the treatment of central nervous system lymphoma (CNSL), including primary CNS lymphoma (PCNSL) and secondary CNS lymphoma. The regimen is often administered with other agents such as rituximab and/or Bruton tyrosine kinase (BTK) inhibitors like orelabrutinib or zanubrutinib to enhance efficacy.
- Other names
- thiotepamethotrexateMTXN,N',N''-triethylenethiophosphoramidetriethylenethiophosphoramideThio-TEPA
02
Targets
DNADHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on thiotepa + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thiotepa + methotrexate.